Connect with us

Uncategorized

Facebook will remove misinformation about covid-19 vaccines

Published

on

The news: Facebook will remove false claims that have been “debunked by public health experts” about covid-19 vaccines, it has announced. In a post, the company outlined how Facebook plans to apply its existing ban on covid misinformation—which is intended to screen out posts that could lead to“ imminent physical harm”—as countries around the world move closer to acquiring and rolling out vaccines. The removals will apply to both Facebook and Instagram.

Effective vaccines are coming: The success of covid-19 vaccines is seen as critical to overcoming the pandemic, with a number of candidates in late stage testing. Earlier this week the UK became the first country to approve a vaccine, granting authorization to use the treatment developed by Pfizer and BioNTech and saying that the first doses could be given to patients within days.

What is Facebook removing? The policy announcement isn’t comprehensive, but it gives a few examples of what would be removed from the site: 

“This could include false claims about the safety, efficacy, ingredients or side effects of the vaccines. For example, we will remove false claims that COVID-19 vaccines contain microchips, or anything else that isn’t on the official vaccine ingredient list. We will also remove conspiracy theories about COVID-19 vaccines that we know today are false: like specific populations are being used without their consent to test the vaccine’s safety.”

So is this a big deal? Simultaneously yes and no. It’s important that Facebook is addressing how it will handle misinformation about vaccinations with more specifics, particularly as we enter what could be the most important public health moment in modern history. Misinformation about vaccines has long thrived on Facebook, and so anything it announces in terms of a ban or major crackdown has the potential to be very consequential.

The “but” here is also important and multifaceted. Facebook’s policies are only as effective as they are enforced. With health misinformation in particular, these bans will only succeed in their aims if they are effectively enforced within the many private groups on Facebook where false health claims are promoted and amplified. This has been an issue with the platform’s previous attempts to crack down on damaging falsehoods.

Uneven enforcement: Even after Facebook began rolling out policies to limit the spread of vaccine misinformation in 2019—by restricting recommendations of groups and hashtags promoting such messages, for example— the anti-vaccine ecosystem continued to thrive in private spaces on the site. Since the pandemic, however, Facebook has been more aggressive about removing some health misinformation, citing its policy against content that could lead to imminent physical harm. A few weeks ago, Facebook banned prominent anti-vaccine personality Larry Cook and an enormous Facebook group he ran for violating its policies about the QAnon conspiracy theory. 

Continue Reading
Comments

Uncategorized

Last-mile delivery robotics company Refraction AI raises $4.2M

Published

on

Ann Arbor-based Refraction AI announced today that it has raised a $4.2 million seed round. The startup, which debuted on the TechCrunch Sessions: Mobility stage back in 2019, was founded by a pair of University of Michigan professors (Matthew Johnson-Roberson — now CTO — and Ram Vasudevan) seeking to solve a number of issues posed by many delivery robots.

With an initial prototype built on a bicycle foundation, the company’s REV-1 robot is designed to operate in bike lanes and roads, rather than the standard sidewalk ‘bot. The different approach allows the robot to travel at higher speeds (topping out at 15 miles per hour) and removes some of the messy pedestrian-dodging issues that come with sidewalk use (while introducing some new ones on that narrow sliver of asphalt shared by cyclists).

Refraction is currently testing a small fleet in its native Ann Arbor. The seed round, led by Pillar VC, will be used for R&D, expanding the company’s reach and recruiting more customers, with a focus on grocery store and restaurant deliveries. Other investors include, eLab Ventures, Osage Venture Partners, Trucks Venture Capital, Alumni Ventures Group, Chad Laurans and Invest Michigan.

Another key differentiator is the use of cameras, versus LIDAR. The decision comes with some technological trade-offs, but benefits include a lower price point and the ability for the company to more quickly scale its fleet. The technology is also not easily districted by weather conditions encountered in the upper midwest, though it has limitations, too. As the company puts it, if you’re not comfortable walking out in it, the robot probably won’t be, either.

“Our platform uses technology that exists today in an innovative way, to get people the things they need, when they need them, where they live,” CEO Luke Schneider said in a release tied to the news. “And we’re doing so in a way that reduces business’ costs, makes roads less congested, and eliminates carbon emissions.”

With this new funding, the company plans to expand operations beyond its native Ann Arbor, though no additional test markets have been announced.

Continue Reading

Uncategorized

New clinical trial data from Locus Biosciences shows promise in CRISPR-Cas3 technology

Published

on

Antibiotic resistance is one of the biggest potential threats to global health today. But Locus Biosciences is hoping that their crPhage technology might provide a new solution.

Based in North Carolina’s Research Triangle, the startup recently announced promising phase 1b clinical trial results for their use of CRISPR-Cas3-enhanced bacteriophages as a treatment for urinary tract infections caused by escherichia coli. Led in part by former Patheon executive and current Locus CEO Paul Garofolo, the startup launched in 2015 with the goal of using a less popular application of CRISPR technology to address growing antimicrobial resistance.

CRISPR-Cas3 technology has notably different mechanisms from its more well-known CRISPR-Cas9 counterpart. Where the Cas9 enzyme has the ability to cleanly cut through a piece of DNA like a pair of scissors, Garofolo describes Cas3 more like a Pac-Man, shredding the DNA as it moves along a strand.

“You wouldn’t be able to use it for most of the editing platforms people were after,” he said, noting that meant there wouldn’t be as much competition around Cas3. “So I knew it would be protected for some time, and that we could keep it quiet.”

Garofolo and his team wanted to use CRISPR-Cas3 not to edit harmful bacteria found in the body, but to destroy it. To do this, they took the DNA-shredding mechanism of Cas3 and used it to enhance bacteriophages—viruses that can attack and kill different species of bacteria. Together, co-founder and Chief Scientific Officer Dave Ousterout—who has a Ph.D. in biomedical engineering from Duke—thinks this technology offers an extremely direct and targeted way of killing bacteria.

“We armed the phages with this Cas3 system that attacks E. coli, and that sort of dual mechanism of action is what comes together, essentially, as a really potent way to remove just E. coli,” he said in an interview.

That specificity is something that antibiotics lack. Rather than targeting only harmful bacteria in the body, antibiotics typically wipe out all bacteria they come across. “Every time we take antibiotics, we’re not thinking about all the other parts of us that are impacted by the bacteria that do good things,” said Garofolo. But the precision of Locus Biosciences’ crPhage technology means that only the targeted bacteria would be wiped out, leaving those necessary to the body’s normal function intact.

Beyond offering this more specific approach to treatment of pathogens, or any bacteria-based disease, Garofolo and his team also suspect that their approach will also be extremely safe. Though deadly to bacteria, bacteriophages are typically harmless to humans. The safety of CRISPR in humans is well-established, too.

“That’s our secret sauce,” said Garofolo. “We can build drugs that are more powerful than the antibiotics they’re trying to replace, and they use phage, which is probably one of the world’s safest ways to deliver something into the human body.”

While this new technology could certainly help treat pathogens and infectious diseases, Garofolo hopes that indications in immunology, oncology, and neurology might benefit from it too. “We’re starting to figure out that some bacteria might promote cancer, or inflammation in your gut,” he said. If researchers can identify the bacteria at the root cause of those conditions, Garofolo and Ousterout think the crPhage technology might prove to be an effective treatment.

“If we’re right about that, it’s not just about infections or antimicrobial resistance, but helping people overcome cancer or delay the onset of dementia,” Garofolo said. “It’s changing the way we think about how bacteria really help us live.”


Early Stage is the premier ‘how-to’ event for startup entrepreneurs and investors. You’ll hear first-hand how some of the most successful founders and VCs build their businesses, raise money and manage their portfolios. We’ll cover every aspect of company-building: Fundraising, recruiting, sales, product market fit, PR, marketing and brand building. Each session also has audience participation built-in – there’s ample time included for audience questions and discussion.


Continue Reading

Uncategorized

Amazon expands its food delivery service across Bangalore

Published

on

Amazon said on Monday it has expanded its food delivery service, called Amazon Food, across 62 zip codes in Bangalore, in what is the first public update since entering the new category in India last May.

The American e-commerce group said Amazon Food now reaches key localities in Bangalore such as Whitefield, HSR, Sarjapur, Koramangala, Indiranagar, MG Road, Jayanagar, JP Nagar, Frazer Town, Malleshwaram, Rajajinagar, and Vijayanaga.

At the time of the launch in May last year, Amazon Food was available in just four zip codes in Bangalore.

Even as Amazon Food remains limited to one key market in India, the company is aggressively trying to undercut the competition — heavily funded startups Zomato and Swiggy — in the city.

Food delivery is free to Prime members, while others have to pay a fee of 19 Indian rupees (26 cents) — cheaper than fees levied by Swiggy and Zomato.

The company, which has committed to investing $6.5 billion in its India operations, said it has amassed 2,5000 restaurants and cloud kitchens in Bangalore — also referred as Bengaluru. Amazon Food customers can enjoy “offers” from these restaurants as well as cashbacks from Amazon, the company said.

It, however, did not share why it has been uncharacteristically so slow with the expansion of Amazon Food in the country.

(Well, I mean, there is a global pandemic — but Amazon also makes a number of what its employees say “one-way door” and “two-way door” bets. Two-way door bets are those that the company has not fully committed to and is just attempting to test the waters before making a concrete decision. Think of Amazon Prime as a one-way door bet. So it’s not clear from day 1 how committed Amazon is to any new service.)

“With the expansion of Amazon Food in Bengaluru, we continue in our endeavor to offer unmatched convenience and value while being a part of their everyday lives. Amazon Food brings some of the city’s top restaurants including national outlets and as well as local favorites which are popular and follow strict delivery and safety protocols,” said Sameer Khetarpal, Director of Category Management at Amazon India, in a statement.

Ant Financial-backed Zomato and Prosus Ventures-backed Swiggy have established duopoly in the food delivery market in India, with analysts at Bank of America estimating their combined market share to be over 90%. (Uber exited the Indian food delivery market early last year after selling its local food business to Zomato.)

The expansion of Amazon Food also comes at a time when Zomato, which according to analysts leads the market, is preparing to file for an IPO.

India’s food delivery market is especially tough to crack because of local conditions. Unlike in the developed markets such as the U.S., where the value of each delivery item is about $33, in India, a similar item carries the price tag of $4, according to research firms. Both Zomato and Swiggy have significantly improved their unit economics in the past year.

Continue Reading

Trending